Chronicle Bio announces first clinical trial with Prolong, using AI to match patients for ME/CFS drug
thekaransinghal · x · 2026-11-13
Chronicle announced its first clinical trial: partnering with Prolong to test Sanguinate, an investigational IV therapy that boosts oxygen delivery and blood flow, for post-exertional malaise in ME/CFS patients. The multi-site Phase 2a trial plans to enroll at least 40 patients, with first dosing expected mid-2027. Unlike symptom-only recruitment, the trial will use Chronicle's endotype intelligence platform, built on 200TB of biological data, to identify hypoxic patients more likely to respond. The company went from creation to first trial in under two years.
More from Companies & People
- One year since Nat Eliason joined a high school where students build $1M+ businesses — nateliason · 2026-11-13
- Nvidia went 33 years without a board chair: AI's governance problem — Pupating-Antenna-36 · 2026-11-13
- Gradient Labs Hosts First HCI Paper Reading Club in London, Three-Hour Deep Dive — round · 2026-11-13
- Matt Wolfe's weekly AI news video spotlights major NVIDIA leadership news — Matt Wolfe · 2026-11-13
- Founder fury: builder ousted over personal life sparks control-rights debate — ShanRizvi · 2026-11-13
- Anthropic launches Claude for Manufacturing — JensHonack · 2026-11-13